|
Research article
VEGF-C and podoplanin, as biomarkers of sepsis. An experimental study
Emoke Almasy, Janos Szederjesi, Bianca-Liana Grigorescu, Simona Gurzu, Alexandra Lazar, Gergo Raduly, Adrian Man, Madalina Oprica, Irina Saplacan, Sanda-Maria Copotoiu
Abstract: Background: Sepsis is the leading cause of morbidity and mortality in intensive care units. This study explored the possible role of vascular endothelial growth factor-C (VEGF-C) and podoplanin (PDPN) in sepsis. Methods: 22 Wistar rats were divided into three groups: two experimental (Group A and B, n=8/8) and a control (Group C, n=6). Sepsis was induced with intraperitoneal injection of ESBL (extended-spectrum beta-lactamases)-producing E-coli live bacteria for group A and with lipopolysaccharide for group B. Sterile saline solution was injected for group C. Blood samples were collected after 24 hours to determine the serum level of VEGF-C, and PDPN expression was examined in liver, kidney, and lung tissues. Bacteremia was assessed for group A. Results: Higher serum levels of VEGF-C were found in Group A vs C (p=0.05) and group B vs. C (p=0.004), respectively.VEGF-C was also increased in animals with negative- vs. positive blood cultures from group A (p=0.04) and from group B vs. those with positive blood cultures from group A (p=0.03). High intensity of PDPN tissue expression was observed in the pulmonary alveolocytes from Group A and epithelium of the proximal renal tubules in groups B and C, compared to group A. Conclusions: Circulating VEGF-C can be succesfuly used as a biomarker of sepsis with negative blood cultures and high risk of renal failure, whereas PDPN seems to exert a protective role against lung injuries in live bacteria-induced sepsis.
Keywords: podoplanin, vascular endothelial growth factor, sepsis, lipopolysaccharide
Received: 1.9.2021
Accepted: 27.9.2021
Published: 1.10.2021
|
|
|
Almasy E, Szederjesi J, Grigorescu BL, Gurzu S, Lazar A, Raduly G, et al. VEGF-C and podoplanin, as biomarkers of sepsis. An experimental study. Rev Romana Med Lab. 2021;29(4):403-12. DOI:10.2478/rrlm-2021-0030
|